135 related articles for article (PubMed ID: 37670407)
1. Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy.
Zha Z; Ploessl K; Choi SR; Zhao R; Jin W; Wang R; Alexoff D; Zhu L; Kung HF
J Med Chem; 2023 Sep; 66(17):12602-12613. PubMed ID: 37670407
[TBL] [Abstract][Full Text] [Related]
2. New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177).
Zha Z; Choi SR; Li L; Zhao R; Ploessl K; Yao X; Alexoff D; Zhu L; Kung HF
J Med Chem; 2022 Oct; 65(19):13001-13012. PubMed ID: 36103652
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
4. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
5.
Dai R; Cai Z; Hu R; Huang Y; Fu L; Yang J; Hu K; Li H
Mol Pharm; 2024 Feb; 21(2):883-894. PubMed ID: 38155100
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Value of post-therapy
Tuncel M; Telli T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):114-117. PubMed ID: 28750750
[TBL] [Abstract][Full Text] [Related]
8. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
10. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
[TBL] [Abstract][Full Text] [Related]
11. Albumin-Binding and Conventional PSMA Ligands in Combination with
Tschan VJ; Busslinger SD; Bernhardt P; Grundler PV; Zeevaart JR; Köster U; van der Meulen NP; Schibli R; Müller C
J Nucl Med; 2023 Oct; 64(10):1625-1631. PubMed ID: 37442604
[TBL] [Abstract][Full Text] [Related]
12. Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer.
Lee BS; Kim MH; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim HS; Kim MH; Kil HS; Han SJ; Lee YJ; Lee KC; Lim SM; Chi DY
Mol Cancer Ther; 2021 Dec; 20(12):2410-2419. PubMed ID: 34725194
[TBL] [Abstract][Full Text] [Related]
13. Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands.
Kuo HT; Zhang Z; Zhang C; Merkens H; Tan R; Wong AAWL; Uribe CF; Bénard F; Lin KS
Theranostics; 2023; 13(13):4559-4573. PubMed ID: 37649602
[TBL] [Abstract][Full Text] [Related]
14. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Ruigrok EAM; van Vliet N; Dalm SU; de Blois E; van Gent DC; Haeck J; de Ridder C; Stuurman D; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1339-1350. PubMed ID: 33094433
[TBL] [Abstract][Full Text] [Related]
15. An Improved
Mease RC; Kang CM; Kumar V; Banerjee SR; Minn I; Brummet M; Gabrielson KL; Feng Y; Park A; Kiess AP; Sgouros G; Vaidyanathan G; Zalutsky MR; Pomper MG
J Nucl Med; 2022 Feb; 63(2):259-267. PubMed ID: 34088772
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of PSMA target diagnostic PET tracers for therapeutic monitoring of [
Kim MH; Lee K; Oh K; Kim CH; Kil HS; Lee YJ; Lee KC; Chi DY
Biochem Biophys Res Commun; 2023 Apr; 651():107-113. PubMed ID: 36801611
[TBL] [Abstract][Full Text] [Related]
17. The role of Ga
Erdogan M; Sengul SS; Cetin B; Avcı M; Yagci S; Ozkoç I; Barikan DE; Yildiz M
Ann Nucl Med; 2022 Jun; 36(6):562-569. PubMed ID: 35397091
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a Radio-IMmunoStimulant (RIMS) in a Syngeneic Model of Murine Prostate Cancer and ImmunoPET Analysis of T-cell Distribution.
Śmiłowicz D; Schlyer D; Boros E; Meimetis L
Mol Pharm; 2022 Sep; 19(9):3217-3227. PubMed ID: 35895995
[TBL] [Abstract][Full Text] [Related]
19.
Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
[TBL] [Abstract][Full Text] [Related]
20. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
